Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results

22.02.2024 - Continued Focus on Expanding Product Portfolio, Market Leadership and InnovationSAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) - Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to ...

Related Keywords

Japan ,Canada ,Ukraine ,Gaza Strip ,China ,Maravai Lifesciences ,Deb Hart Maravai Lifesciences ,Trey Martin ,Becky Buzzeo ,Vector Laboratories Inc ,Maravai Lifesciences Holdings Inc ,Nucleic Acid Production ,Exchange Commission ,Healthcare Technology ,Maravai Topco Holdings ,Fujifilm ,Link Biotechnologies ,Glen Report ,Chief Commercial Officer ,Healthcare Technology Report ,Chief Executive ,Fourth Quarter ,Months Ended December ,Full Year ,Ended December ,Acid Production ,Safety Testing ,Tax Receivable Agreement ,Maravai Lifesciences Holdings ,Receivable Agreement ,Executive Officer ,Net Income ,Adjusted Fully Diluted Earnings Per ,Chief Executive Officer ,Cost Realignment Plan ,Vector Laboratories ,Topco Holdings ,Tax Receivable ,Earnings Per Share ,Adjusted Net ,Adjusted Diluted ,Maravai Topco ,Securities Litigation Reform Act ,Financial Condition ,Annual Report ,Quarterly Reports ,Contact Information ,Investor Contact ,Chelsea Rule Macdougall Advisors ,Maravai Lifesciences Holdings Registereda Chart ,Aravai Lifesciences Holdings Registereda Kurs ,Aravai Lifesciences Holdings Registereda Aktie ,